. 2006 Feb 21;55(12):1553–1564. doi: 10.1007/s00262-006-0145-7

Table 2.

Characteristics of included patients and summary of responses and survival for the individual patients

	Treatment, week 1–12										Follow-up
	Patient No	Age	Sex	Previous treatment	Tumor histology	Stage	No. of injects	DTH/T cells	Compl. Study	Disease status w12	No. of booster injects	DTH T cells	Survival months from start of treatment
Low dose	701	60	M	Dc/Rad	Nsclc	IIIB	8	−/−	Yes	SD			11
	702	69	M	Dc/P	Adeno	IV	6	W	No	PD			4
	703	68	F	Rad	Adeno	IV	8	+/−	Yes	PD			15
	704	60	F	Opr/Rad	Adeno	IV	8	+/+	Yes	SD			18
	706	60	M	Dc	nsclc	IV	8	+/−	Yes	PD			3
	707	59	M	P	adeno	IV	6	−/−	No	PD			2.5
	708	39	M	Dc/P	squam	IV	8	+/+	Yes	SD			7
	709	63	F	Dc/P/Rad	squam	IV	6	W	No	PD			3
	710	55	M	P/Rad	adeno	IIIA	8	−/−	Yes	SD	13	−/+	46^a
	711	48	M	Dc	squam	IV	8	+/+	Yes	PD			25
	712	49	F	Opr/Dc/P	adeno	IV	8	+/+	Yes	SD	8	−/+	44^a
	713	76	F	Rad	squam	IIIB	8	+/+	Yes	PD			19
High dose	714	68	M	Rad	squam	IV	8	+/−	Yes	PD			32
	715	45	F	P/Rad/Dc	adeno	IV	4	W	No	PD			5
	716	72	M	Rad	nsclc	IV	6	W	No	PD			1.5
	717	56	M	P/NP/Dc	squam	IV	7	W	No	PD			2.5
	718	57	F	None	adeno	IV	6	W	No	PD			4
	719	44	M	P/Rad	adeno	IV	7	W	No	PD			3.5
	720	57	F	Rad	largecell	IV	4	W	No	NE			8.5
	721	63	F	P/Dc/P	nsclc	IV	7	+/+	No	PD			5.5
	722	60	F	Rad/P	adeno	IV	6	W	No	PD			4
	723	53	M	Opr/Rad/Dc	squam	IV	8	−/+	Yes	PD			16.5
	724	60	F	None	bronch	IV	8	−/−	Yes	PD			10
	725	55	F	Opr	adeno	IIB	8	+/−	Yes	SD	3	+/+	30^a
	726	49	M	P	adeno	IV	7	−/−	No	PD			3.5
	727	57	M	Opr/Dc/Rad	squam	IIIB	8	−/−	Yes	SD	6	−/+	29^a

Dc docetaxel, P platinum, NP non-platinum, Rad radiation, Opr operation, W withdrawn

^aAlive at time of reporting